Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

CORIMUNO-SARI-1 (non ICU)
  NCT04324073		 RCTsarilumabstandard of careCOVID 19 hospitalizedsome concern
68/80 inconclusive
  • inconclusive 1 % increase in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
  • inconclusive 12 % increase in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
Declercq J (COV-AID)
  NCT04330638		 RCTtocilizumab standard of careCOVID 19 hospitalizedlow
114/115 inconclusive
    RCT-TCZ-COVID-19
          NCT04346355    		 RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
    		60/66 inconclusive
      RECOVERY
              NCT04381936      		 RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
      		2022/2094 conclusif
      • demonstrated 15 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
      • suggested 15 % decrease in death or ventilation with a moderate degree of certainty due to some concern in risk of bias
      Rutgers RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
      		174/180 suggested
      • inconclusive 41 % decrease in death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias
      • suggested 35 % decrease in death or ventilation with a moderate degree of certainty due to some concern in risk of bias
      Soin AS (COVINTOC)
              CTRI/2020/05/025369      		 RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
      		90/90 inconclusive
        Dongsheng Wang
                  ChiCTR2000029765        		 RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
        		33/32 safety concern
        • statistically significant 8.6-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
        EU-CTR2020-001375-32 (PreToVid) unpublished
                  EU-CTR2020-001375-32        		 RCTtocilizumab standard of careCOVID 19 hospitalizedlow
        		174/180 inconclusive
          EU-CTR2020-001748-24 (ImmCoVA) unpublished
                      EU-CTR2020-001748-24          		 RCTtocilizumab standard of careCOVID 19 hospitalizedlow
          		22/27 inconclusive
            NCT04434717 (COVITOZ-1 single dose plus two doses) unpublished
                          NCT04434717            		 RCTtocilizumab standard of careCOVID 19 hospitalizedlow
            		17/9 inconclusive
              NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg) unpublished
                              NCT04479358              		 RCTtocilizumab standard of careCOVID 19 hospitalizedlow
              		20/8 inconclusive
                NCT04577534 (COVIDSTORM) unpublished
                                  NCT04577534                		 RCTtocilizumab standard of careCOVID 19 hospitalizedlow
                		26/13 inconclusive

                  COVID 19 all comers meta-analysis

                  TOCOVID unpublished
                                      NCT04332094                  		 RCTtocilizumab standard of careCOVID 19 all comersNA
                  		136/134 inconclusive

                    COVID-19 severe or critically meta-analysis

                    Hamed RCTtocilizumab standard of careCOVID-19 severe or criticallyhigh
                    		26/23 inconclusive
                    • inconclusive 83 % increase in deaths (PE) but with a low degree of certainty due to high risk of bias
                    • inconclusive 2.2-fold increase in ICU admission (PE) but with a low degree of certainty due to high risk of bias
                    REMAP-CAP (tocilizumab)
                                          NCT02735707                    		 RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
                    		353/402 conclusif
                    • suggested 30 % decrease in deaths with a moderate degree of certainty due to some concern in risk of bias
                    • demonstrated 64 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
                    REMAP-CAP sarilumab
                                          NCT02735707                    		 RCTsarilumabstandard of careCOVID-19 severe or criticallyhigh
                    		48/402 conclusif
                    • demonstrated 76 % increase in clinical improvement (PE) but with a low degree of certainty due to high risk of bias
                    • suggested 86 % increase in clinical improvement (14-day) but with a low degree of certainty due to high risk of bias
                    Talaschian
                                          IRCT20081027001411N4                    		 RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
                    		20/20 inconclusive
                      Veiga
                                              NCT04403685                      		 RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
                      		65/64 safety concern
                      • safety concern with 1.7-fold increase in deaths,death D28 (not statistically significant)
                      • inconclusive 54 % increase in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
                      CORIMUNO-TOCI-1 (Group 1)
                                              NCT04331808                      		 RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
                      		64/67 inconclusive
                        CORIMUNO-TOCI-ICU (Group 2)
                                                  NCT04331808                        		 RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
                        		49/43 inconclusive

                          PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
                          Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

                           

                          - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons